On September 14, 2023, the Federal Trade Commission (FTC) issued a statement condemning pharmaceutical manufacturers’ improper inclusion of patents in the Food and Drug Administration’s (FDA’s) ...
Expansion to FTC’s Orange Book Campaign Leads to Calls for More Clarity from Pharmaceutical Industry
“The FTC acts as if the agency is being perfectly clear on what it’s subjecting companies to, but there’s never been a conversation around what it means for a patent to claim a drug product.” – Hans ...
To advance policies that secure the future of a leading U.S. innovative industry, it is important in this instance to gain a deeper understanding of what generic drugs are, what the FTC is challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback